Inge Lues
Halle, NI 06120, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice.
Journal: International journal of molecular sciences
Published: September 06, 2021
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation.
Journal: Scientific reports
Published: November 03, 2019
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice.
Journal: Alzheimer's research & therapy
Published: October 23, 2019
In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease.
Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
Published: January 30, 2019
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Journal: Alzheimer's research & therapy
Published: May 15, 2018
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives.
Journal: Molecules (Basel, Switzerland)
Published: March 29, 2018
Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
Journal: Molecules (Basel, Switzerland)
Published: March 20, 2018
Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.
Journal: The Journal of pharmacology and experimental therapeutics
Published: February 07, 2017
Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy.
Journal: The Journal of biological chemistry
Published: January 31, 2017
Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
Journal: Alzheimer's research & therapy
Published: January 26, 2017
A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.
Journal: Alzheimer's & dementia (New York, N. Y.)
Published: October 03, 2015
An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.
Journal: Neurobiology of aging
Published: December 03, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026